Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.

被引：10

作者：

Apolo, Andrea B.

Infante, Jeffrey R.

Hamid, Omid

Patel, Manish R.

Wang, Ding

Kelly, Karen

Mega, Anthony E.

Britten, Carolyn D.

Mita, Alain C.

Ravaud, Alain

Cuillerot, Jean-Marie

von Heydebreck, Anja

Gulley, James L.

机构：

[1] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[2] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA

[3] Angeles Clin & Res Inst, Los Angeles, CA USA

[4] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[5] Henry Ford Hosp, Detroit, MI 48202 USA

[6] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA

[7] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA

[8] Med Univ S Carolina, Charleston, SC 29425 USA

[9] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA

[10] CHU Bordeaux, Hop St Andre, Bordeaux, France

[11] EMD Serono, Billerica, MA USA

[12] Merck KGaA, Darmstadt, Germany

[13] NCI, NIH, Bethesda, MD 20892 USA

来源：

关键词：

D O I：

10.1200/jco.2016.34.2_suppl.367

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

367

引用

页数：1